Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Net Asset Quality Index
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Net Asset Quality Index of 94.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.89 Billion minus total liabilities of CN¥161.98 Million yields net assets of CN¥2.73 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2009–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the index stands at 94.4%, representing net assets of CN¥2.73 Billion against total assets of CN¥2.89 Billion CNY. For live market cap and overall valuation, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) total market value.
Annual Net Asset Quality Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.8% | CN¥2.46 Billion | CN¥2.71 Billion | CN¥250.30 Million | ▲ +0.8 pp |
| 2023 | 89.9% | CN¥2.30 Billion | CN¥2.56 Billion | CN¥258.46 Million | ▼ -2.3 pp |
| 2022 | 92.2% | CN¥2.03 Billion | CN¥2.20 Billion | CN¥170.76 Million | ▼ -0.8 pp |
| 2021 | 93.0% | CN¥1.80 Billion | CN¥1.93 Billion | CN¥135.36 Million | ▼ -2.2 pp |
| 2020 | 95.2% | CN¥1.53 Billion | CN¥1.60 Billion | CN¥76.61 Million | ▲ +0.6 pp |
| 2019 | 94.7% | CN¥1.35 Billion | CN¥1.43 Billion | CN¥76.25 Million | ▲ +0.6 pp |
| 2018 | 94.1% | CN¥995.42 Million | CN¥1.06 Billion | CN¥62.47 Million | ▼ -0.4 pp |
| 2017 | 94.5% | CN¥801.26 Million | CN¥848.31 Million | CN¥47.05 Million | ▲ +0.4 pp |
| 2016 | 94.1% | CN¥655.58 Million | CN¥696.89 Million | CN¥41.32 Million | ▼ -1.3 pp |
| 2015 | 95.3% | CN¥582.91 Million | CN¥611.49 Million | CN¥28.57 Million | ▼ -1.3 pp |
| 2014 | 96.7% | CN¥513.55 Million | CN¥531.31 Million | CN¥17.75 Million | ▲ +1.2 pp |
| 2013 | 95.4% | CN¥251.92 Million | CN¥263.95 Million | CN¥12.04 Million | ▲ +0.5 pp |
| 2012 | 94.9% | CN¥181.38 Million | CN¥191.11 Million | CN¥9.73 Million | ▲ +8.2 pp |
| 2011 | 86.7% | CN¥127.61 Million | CN¥147.19 Million | CN¥19.58 Million | ▲ +4.9 pp |
| 2010 | 81.8% | CN¥90.44 Million | CN¥110.52 Million | CN¥20.08 Million | ▼ -10.3 pp |
| 2009 | 92.2% | CN¥111.89 Million | CN¥121.38 Million | CN¥9.49 Million | — |